;PMID: 3878657
;source_file_1926.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..54] = [t:0..54]
;1)sentence:[e:60..195] = [t:60..195]
;2)section:[e:199..234] = [t:199..234]
;3)sentence:[e:238..407] = [t:238..407]
;4)sentence:[e:408..643] = [t:408..643]
;5)sentence:[e:644..794] = [t:644..794]
;6)sentence:[e:796..1073] = [t:796..1073]
;7)sentence:[e:1074..1135] = [t:1074..1135]
;8)sentence:[e:1136..1303] = [t:1136..1303]
;9)sentence:[e:1304..1486] = [t:1304..1486]
;10)section:[e:1490..1534] = [t:1490..1534]

;section 0 Span:0..54
;Acta Pharmacol Toxicol (Copenh). 1985 Oct;57(4):250-4.
(SEC
  (FRAG (NNP:[0..4] Acta) (NNP:[5..14] Pharmacol) (NNP:[15..22] Toxicol)
        (-LRB-:[23..24] -LRB-) (NN:[24..30] Copenh) (-RRB-:[30..31] -RRB-)
        (.:[31..32] .) (CD:[33..37] 1985) (.:[38..44] Oct;57)
        (-LRB-:[44..45] -LRB-) (CD:[45..46] 4) (-RRB-:[46..47] -RRB-)
        (CD:[47..54] :250-4.)))

;sentence 1 Span:60..195
;Inhibition by methylglyoxal bis(guanylhydrazone) of drug oxidation reactions 
;catalyzed by mouse liver microsomes in vivo and in vitro.
;[74..108]:substance:"methylglyoxal bis(guanylhydrazone)"
;[112..116]:substance:"drug"
(SENT
  (NP-HLN
    (NP (NN:[60..70] Inhibition))
    (PP (IN:[71..73] by)
      (NP (NN:[74..87] methylglyoxal)
          (NN:[88..108] bis-LRB-guanylhydrazone-RRB-)))
    (PP (IN:[109..111] of)
      (NP
        (NP (NN:[112..116] drug) (NN:[117..126] oxidation)
            (NNS:[127..136] reactions))
        (VP (VBN:[138..147] catalyzed)
          (NP (-NONE-:[147..147] *))
          (PP (IN:[148..150] by)
            (NP-LGS (NN:[151..156] mouse) (NN:[157..162] liver)
                    (NNS:[163..173] microsomes)))
          (ADVP
            (ADVP (FW:[174..176] in) (FW:[177..181] vivo))
            (CC:[182..185] and)
            (ADVP (FW:[186..188] in) (FW:[189..194] vitro))))))
    (.:[194..195] .)))

;section 2 Span:199..234
;Kaipainen PM, Karvonen EH, Poso HJ.
(SEC
  (FRAG (NNP:[199..208] Kaipainen) (NNP:[209..211] PM) (,:[211..212] ,)
        (NNP:[213..221] Karvonen) (NNP:[222..224] EH) (,:[224..225] ,)
        (NNP:[226..230] Poso) (NNP:[231..234] HJ.)))

;sentence 3 Span:238..407
;The activity of coumarin 7-hydroxylase (coumarin 7-hydroxylation) was
;inhibited  in B6 mouse liver after a single injection of methylglyoxal
;bis(guanylhydrazone  (MGBG).
;[254..276]:cyp450:"coumarin 7-hydroxylase"
;[278..286]:substance:"coumarin"
;[365..398]:substance:"methylglyoxal bis(guanylhydrazone"
;[401..405]:substance:"MGBG"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[238..241] The) (NN:[242..250] activity))
      (PP (IN:[251..253] of)
        (NP
          (NP (NN:[254..262] coumarin) (NN:[263..276] 7-hydroxylase))
          (NP (-LRB-:[277..278] -LRB-) (NN:[278..286] coumarin)
              (NN:[287..302] 7-hydroxylation) (-RRB-:[302..303] -RRB-)))))
    (VP (VBD:[304..307] was)
      (VP (VBN:[308..317] inhibited)
        (NP-1 (-NONE-:[317..317] *))
        (PP-LOC (IN:[319..321] in)
          (NP (NN:[322..324] B6) (NN:[325..330] mouse) (NN:[331..336] liver)))
        (PP-TMP (IN:[337..342] after)
          (NP
            (NP (DT:[343..344] a) (JJ:[345..351] single)
                (NN:[352..361] injection))
            (PP (IN:[362..364] of)
              (NP
                (NP (NN:[365..378] methylglyoxal)
                    (NN:[379..398] bis-LRB-guanylhydrazone))
                (NP (-LRB-:[400..401] -LRB-) (NN:[401..405] MGBG)
                    (-RRB-:[405..406] -RRB-))))))))
    (.:[406..407] .)))

;sentence 4 Span:408..643
;The decrease in the activity in vivo was greatest (70%) one day after  the
;drug injection and the hydroxylase activity in microsomal fraction prepared 
;from livers of MGBG-treated B6 mice was still 25% decreased 5 days after the 
;drug.
;[459..462]:quantitative-value:"70%"
;[464..467]:quantitative-value:"one"
;[468..471]:quantitative-units:"day"
;[483..487]:substance:"drug"
;[506..517]:substance:"hydroxylase"
;[575..579]:substance:"MGBG"
;[606..609]:quantitative-value:"25%"
;[620..621]:quantitative-value:"5"
;[622..626]:quantitative-units:"days"
;[638..642]:substance:"drug"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[408..411] The) (NN:[412..420] decrease))
        (PP (IN:[421..423] in)
          (NP (DT:[424..427] the) (NN:[428..436] activity)))
        (ADJP (FW:[437..439] in) (FW:[440..444] vivo)))
      (VP (VBD:[445..448] was)
        (ADJP-PRD (JJS:[449..457] greatest)
          (PRN (-LRB-:[458..459] -LRB-)
            (NP (CD:[459..461] 70) (NN:[461..462] %))
            (-RRB-:[462..463] -RRB-)))
        (PP-TMP
          (NP-ADV (CD:[464..467] one) (NN:[468..471] day))
          (IN:[472..477] after)
          (NP (DT:[479..482] the) (NN:[483..487] drug) (NN:[488..497] injection)))))
    (CC:[498..501] and)
    (S
      (NP-SBJ-1
        (NP (DT:[502..505] the) (NN:[506..517] hydroxylase)
            (NN:[518..526] activity))
        (PP (IN:[527..529] in)
          (NP
            (NP (JJ:[530..540] microsomal) (NN:[541..549] fraction))
            (VP (VBN:[550..558] prepared)
              (NP (-NONE-:[558..558] *))
              (PP (IN:[560..564] from)
                (NP
                  (NP (NNS:[565..571] livers))
                  (PP (IN:[572..574] of)
                    (NP
                      (ADJP (NN:[575..579] MGBG) (HYPH:[579..580] -)
                            (VBN:[580..587] treated))
                      (NN:[588..590] B6) (NNS:[591..595] mice)))))))))
      (VP (VBD:[596..599] was)
        (ADVP (RB:[600..605] still))
        (NP-EXT (CD:[606..608] 25) (NN:[608..609] %))
        (VP (VBN:[610..619] decreased)
          (NP-1 (-NONE-:[619..619] *))
          (PP-TMP
            (NP-ADV (CD:[620..621] 5) (NNS:[622..626] days))
            (IN:[627..632] after)
            (NP (DT:[633..636] the) (NN:[638..642] drug))))))
    (.:[642..643] .)))

;sentence 5 Span:644..794
;The amount of cytochrome P-450 also was decreased in MGBG-treated livers 
;with the same time-dependency as the inhibition of coumarin 7-hydroxylation.
;[658..674]:cyp450:"cytochrome P-450"
;[697..701]:substance:"MGBG"
;[769..777]:substance:"coumarin"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[644..647] The) (NN:[648..654] amount))
      (PP (IN:[655..657] of)
        (NP (NN:[658..668] cytochrome) (NN:[669..674] P-450))))
    (ADVP (RB:[675..679] also))
    (VP (VBD:[680..683] was)
      (VP (VBN:[684..693] decreased)
        (NP-1 (-NONE-:[693..693] *))
        (PP-LOC (IN:[694..696] in)
          (NP
            (NP
              (ADJP (NN:[697..701] MGBG) (HYPH:[701..702] -)
                    (VBN:[702..709] treated))
              (NNS:[710..716] livers))
            (PP (IN:[718..722] with)
              (NP
                (NP (DT:[723..726] the) (JJ:[727..731] same)
                    (NN:[732..736] time) (HYPH:[736..737] -)
                    (NN:[737..747] dependency))
                (PP (IN:[748..750] as)
                  (NP
                    (NP (DT:[751..754] the) (NN:[755..765] inhibition))
                    (PP (IN:[766..768] of)
                      (NP (NN:[769..777] coumarin)
                          (NN:[778..793] 7-hydroxylation)))))))))))
    (.:[793..794] .)))

;sentence 6 Span:796..1073
;MGBG and its close derivative 
;1,1'-[methylethanediylidene)dinitrilo)bis(3-aminoguanidine) (MBAG) inhibited
;the  activity in vitro of coumarin 7-hydroxylase, benzo(a)pyrene hydroxylase
;and  7-ethoxy 0-de-ethylase when microsomes were prepared from livers of
;untreated B6  mice.
;[796..800]:substance:"MGBG"
;[815..825]:substance:"derivative"
;[827..886]:substance:"1,1'-[methylethanediylidene)dinitrilo)bis(3-aminoguanid
;ine)"
;[888..892]:substance:"MBAG"
;[930..952]:cyp450:"coumarin 7-hydroxylase"
;[954..980]:cyp450:"benzo(a)pyrene hydroxylase"
;[986..1008]:substance:"7-ethoxy 0-de-ethylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[796..800] MGBG))
      (CC:[801..804] and)
      (NP
        (NP (PRP$:[805..808] its) (JJ:[809..814] close)
            (NN:[815..825] derivative))
        (NP
          (NP
              (NN:[827..886] 1,1'--LSB-methylethanediylidene-RRB-dinitrilo-RRB-bis-LRB-3-aminoguanidine-RRB-))
          (NP (-LRB-:[887..888] -LRB-) (NN:[888..892] MBAG)
              (-RRB-:[892..893] -RRB-)))))
    (VP (VBD:[894..903] inhibited)
      (NP
        (NP (DT:[904..907] the) (NN:[909..917] activity))
        (ADJP (FW:[918..920] in) (FW:[921..926] vitro))
        (PP (IN:[927..929] of)
          (NP
            (NP (NN:[930..938] coumarin) (NN:[939..952] 7-hydroxylase))
            (,:[952..953] ,)
            (NP (NN:[954..968] benzo-LRB-a-RRB-pyrene)
                (NN:[969..980] hydroxylase))
            (CC:[981..984] and)
            (NP (NN:[986..994] 7-ethoxy) (NN:[995..1008] 0-de-ethylase)))))
      (SBAR-ADV
        (WHADVP-1 (WRB:[1009..1013] when))
        (S
          (NP-SBJ-2 (NNS:[1014..1024] microsomes))
          (VP (VBD:[1025..1029] were)
            (VP (VBN:[1030..1038] prepared)
              (NP-2 (-NONE-:[1038..1038] *))
              (PP (IN:[1039..1043] from)
                (NP
                  (NP (NNS:[1044..1050] livers))
                  (PP (IN:[1051..1053] of)
                    (NP (JJ:[1054..1063] untreated) (NN:[1064..1066] B6)
                        (NNS:[1068..1072] mice)))))
              (ADVP-TMP-1 (-NONE-:[1072..1072] *T*)))))))
    (.:[1072..1073] .)))

;sentence 7 Span:1074..1135
;In every case MBAG was a better inhibitor than MGBG in vitro.
;[1088..1092]:substance:"MBAG"
;[1106..1115]:substance:"inhibitor"
;[1121..1125]:substance:"MGBG"
(SENT
  (S
    (PP (IN:[1074..1076] In)
      (NP (DT:[1077..1082] every) (NN:[1083..1087] case)))
    (NP-SBJ (NN:[1088..1092] MBAG))
    (VP (VBD:[1093..1096] was)
      (NP-PRD
        (NP (DT:[1097..1098] a) (JJR:[1099..1105] better)
            (NN:[1106..1115] inhibitor))
        (PP (IN:[1116..1120] than)
          (NP (NN:[1121..1125] MGBG))))
      (ADVP (FW:[1126..1128] in) (FW:[1129..1134] vitro)))
    (.:[1134..1135] .)))

;sentence 8 Span:1136..1303
;The in vitro  inhibition of MGBG of several drug metabolizing enzymes was not
;reversed when  microsomes were preincubated with 1 mM putrescine, spermidine
;or spermine.
;[1164..1168]:substance:"MGBG"
;[1180..1205]:substance:"drug metabolizing enzymes"
;[1263..1264]:quantitative-value:"1"
;[1265..1267]:quantitative-units:"mM"
;[1268..1278]:substance:"putrescine"
;[1280..1290]:substance:"spermidine"
;[1294..1302]:substance:"spermine"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1136..1139] The)
        (ADJP (FW:[1140..1142] in) (FW:[1143..1148] vitro))
        (NN:[1150..1160] inhibition))
      (PP (IN:[1161..1163] of)
        (NP (NN:[1164..1168] MGBG)))
      (PP (IN:[1169..1171] of)
        (NP (JJ:[1172..1179] several)
          
          (ADJP (NN:[1180..1184] drug) (VBG:[1185..1197] metabolizing))
          (NNS:[1198..1205] enzymes))))
    (VP (VBD:[1206..1209] was) (RB:[1210..1213] not)
      (VP (VBN:[1214..1222] reversed)
        (NP-1 (-NONE-:[1222..1222] *))
        (SBAR-ADV
          (WHADVP-2 (WRB:[1223..1227] when))
          (S
            (NP-SBJ-3 (NNS:[1229..1239] microsomes))
            (VP (VBD:[1240..1244] were)
              (VP (VBN:[1245..1257] preincubated)
                (NP-3 (-NONE-:[1257..1257] *))
                (PP-MNR (IN:[1258..1262] with)
                  (NP
                    (NML (CD:[1263..1264] 1) (NN:[1265..1267] mM))
                    (NN:[1268..1278] putrescine) (,:[1278..1279] ,)
                     (NN:[1280..1290] spermidine) (CC:[1291..1293] or)
                     (NN:[1294..1302] spermine)))
                (ADVP-TMP-2 (-NONE-:[1302..1302] *T*))))))))
    (.:[1302..1303] .)))

;sentence 9 Span:1304..1486
;These  results suggest that the anti-cancer drug, MGBG, has a severe
;effect(s) on the  drug metabolizing system at concentrations reached during
;the treatment of  patients with MGBG.
;[1336..1352]:substance:"anti-cancer drug"
;[1354..1358]:substance:"MGBG"
;[1391..1395]:substance:"drug"
;[1481..1485]:substance:"MGBG"
(SENT
  (S
    (NP-SBJ (DT:[1304..1309] These) (NNS:[1311..1318] results))
    (VP (VBP:[1319..1326] suggest)
      (SBAR (IN:[1327..1331] that)
        (S
          (NP-SBJ
            (NP (DT:[1332..1335] the)
              
              (NML (AFX:[1336..1340] anti) (HYPH:[1340..1341] -)
                   (NN:[1341..1347] cancer))
              (NN:[1348..1352] drug))
            (,:[1352..1353] ,)
            (NP (NN:[1354..1358] MGBG)))
          (,:[1358..1359] ,)
          (VP (VBZ:[1360..1363] has)
            (NP
              (NP (DT:[1364..1365] a) (JJ:[1366..1372] severe)
                  (NN:[1373..1382] effect-LRB-s-RRB-))
              (PP (IN:[1383..1385] on)
                (NP (DT:[1386..1389] the)
                  (ADJP (NN:[1391..1395] drug) (VBG:[1396..1408] metabolizing))
                  (NN:[1409..1415] system))))
            (PP (IN:[1416..1418] at)
              (NP
                (NP (NNS:[1419..1433] concentrations))
                (VP (VBN:[1434..1441] reached)
                  (NP (-NONE-:[1441..1441] *))
                  (PP-TMP (IN:[1442..1448] during)
                    (NP
                      (NP (DT:[1449..1452] the) (NN:[1453..1462] treatment))
                      (PP (IN:[1463..1465] of)
                        (NP (NNS:[1467..1475] patients)))
                      (PP (IN:[1476..1480] with)
                        (NP (NN:[1481..1485] MGBG))))))))))))
    (.:[1485..1486] .)))

;section 10 Span:1490..1534
;PMID: 3878657 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1490..1494] PMID) (::[1494..1495] :) (CD:[1496..1503] 3878657)
        (NN:[1504..1505] -LSB-) (NNP:[1505..1511] PubMed) (::[1512..1513] -)
        (NN:[1514..1521] indexed) (IN:[1522..1525] for)
        (NNP:[1526..1534] MEDLINE-RSB-)))
